The reported discussions between AstraZeneca and Bristol Myers Squibb underscore the continuing drive toward consolidation among the world's largest pharmaceutical companies. Industry leaders are pursuing larger portfolios and stronger research pipelines despite significant regulatory hurdles and investor caution over megadeals.